Yes, Cibinqo Treats Atopic Dermatitis
Cibinqo (abrocitinib) is FDA-approved for moderate-to-severe atopic dermatitis in adults whose skin doesn't fully clear with topical prescription therapies or when those therapies aren't advisable.[1] It's a once-daily oral JAK inhibitor that targets inflammation by blocking Janus kinase enzymes involved in the itch-scratch-immune cycle of eczema.
How Does Cibinqo Work for Atopic Dermatitis?
It inhibits JAK1 specifically, reducing signals that trigger skin inflammation and itching. Clinical trials (JADE MONO-1, JADE MONO-2, JADE COMPARE) showed 39-44% of patients achieving clear or almost clear skin at 12 weeks, compared to 8-13% on placebo. Itch relief starts within days for many.[1][2]
Who Qualifies and When Is It Prescribed?
Prescribed after failing topical corticosteroids, calcineurin inhibitors, or PDE4 inhibitors like crisaborole. Not first-line; requires enrollment in a REMS program due to risks like blood clots, infections, and cancers. Ages 12+ in some approvals outside U.S.[1]
Common Side Effects Patients Report
Nausea (up to 18%), headache (14%), acne (11%), and herpes infections. Serious risks include serious infections, heart issues, and malignancies—black box warning for these. Monitor blood counts before and during use.[1]
How Does It Compare to Dupixent or Rinvoq?
| Drug | Mechanism | Dosing | EASI-75 Response (12 weeks) | Key Differences |
|------|-----------|--------|-----------------------------|-----------------|
| Cibinqo | Oral JAK1 inhibitor | 100/200 mg daily pill | 44% | Fast itch relief; no injections |
| Dupixent (dupilumab) | IL-4/IL-13 monoclonal antibody | SubQ injection every 2-4 weeks | 44-51% | Safer long-term profile; approved for kids 6 months+ |
| Rinvoq (upadacitinib) | Oral JAK1 inhibitor | 15/30 mg daily pill | 60-70% | Slightly higher efficacy; similar risks |
Cibinqo often edges out methotrexate but trails Rinvoq in head-to-head speed.[2][3]
When Did Approval Happen and What's the Patent Status?
FDA approved September 2021 for atopic dermatitis (initially 2020 for rheumatoid arthritis). Pfizer markets it. Key U.S. patents expire around 2031-2033; check DrugPatentWatch.com for litigation updates on challenges.[4]
Cost and Access Options
List price ~$6,000/month (200 mg), but copay cards drop it to $0-25 for eligible insured patients. Medicare caps out-of-pocket at $2,000/year starting 2025. Biosimilars unlikely before 2032.[4]
Sources
[1]: FDA Label for Cibinqo
[2]: NEJM JADE Trials
[3]: JADE COMPARE Study
[4]: DrugPatentWatch.com - Cibinqo